GORE MEDICAL RECEIVES BREAKTHROUGH DEVICE DESIGNATION FOR THE GORE® EXCLUDER® THORACOABDOMINAL BRANCH ENDOPROSTHESIS
CAUTION: Investigational device. Limited by United States law to investigational use.
Apr 12, 2022
First Patient Enrolled in Investigational Study of the GORE® EXCLUDER® Conformable AAA Endoprosthesis with ACTIVE CONTROL System
Investigating the safety and effectiveness of a stent graft system designed to provide endovascular aneurysm repair (EVAR) with angulation control to patients previously considered untreatable
Study Confirms GORE® BIO-A® Tissue Reinforcement a Proven Alternative to Biologics in Hernia Repair
Two-year study demonstrates improved patient satisfaction with Gore material
GORE® EXCLUDER® AAA Endoprosthesis Gore Completes Primary Enrollment for the Gore EXCLUDER® Iliac Branch Clinical Study
62 patients enrolled in US investigational device exemption clinical study to assess first complete, low-profile system for managing common iliac artery aneurysms or aorto-iliac aneurysms
Gore Again Named One of the 100 Best Companies to Work For®
Every year since 1998: That’s how long W. L. Gore & Associates has appeared on the Fortune 100 Best Companies to Work For® list
Nominees Announced for 2016 Pioneers in Performance Awards for North America; Online Voting Opens at www.PioneersInPerformance.com
Awards program honors medical specialists advancing therapy and improving patient and clinical performance through active collaboration
GORE® TIGRIS® Vascular Stent Gains FDA Approval for Treatment of Peripheral Artery Disease
Novel device combines proven technology with modern adaptations to provide support in even the most challenging anatomies
Now Published in the Annals of Surgery: Long-Term Favorable Results Demonstrate GORE® BIO-A® Tissue Reinforcement Efficacy in Complex Ventral Hernia Repairs
Final study results demonstrate for the first time efficacy of long-lasting absorbable biosynthetic mesh in challenging hernia repairs; has potential to end biologics era in hernia repair